Amgen Inc. diskutieren

Amgen Inc. (NASDAQ: AMGN) had its "underperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $215.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $362.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $405.00 price target on the stock.

Hey there! I've been keeping an eye on Amgen, and I've got to say, I'm feeling pretty optimistic about this biotech powerhouse. Sure, there's been some insider selling, which might raise a few eyebrows, but let's not forget the bigger picture. Amgen's diving headfirst into the AI revolution in healthcare, and that's seriously exciting stuff. They're using machine learning to speed up drug discovery and optimize clinical trials - talk about a game-changer! Their recent financial results are pretty impressive too, with a 20% revenue jump in Q4 2023. Plus, they're making waves with their new obesity drug, MariTide. It's like they're cooking up a secret sauce that could give the big players a run for their money. The market for AI in healthcare is exploding, and Amgen's right in the thick of it. It's not all smooth sailing, of course - the competition is fierce, and there are always risks in biotech. But with their solid pipeline and AI investments, I think Amgen's got the potential to be a real winner in the long run. It's like they're planting seeds now that could grow into a mighty forest of profits later. What do you think? Are you ready to ride this biotech wave with Amgen?

Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $380.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at TD Cowen from $381.00 to $383.00. They now have a "buy" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $405.00 price target on the stock.

Hey there, fellow investor! I've been digging into Amgen lately, and I've got to say, I'm pretty excited about what I'm seeing. Sure, the market's been a bit of a rollercoaster, but Amgen seems to be holding its own. Did you catch that news about their potential biosimilar launch? It's like they're gearing up for a big race, and I think they might just have the winning horse. Now, I know the Regeneron situation has got some folks worried, but here's the thing: Amgen's diversity is its strength. It's not putting all its eggs in one basket, you know? Plus, with earnings expected to grow and revenue potentially jumping by nearly 18% this year, it's like they've got rocket fuel in their tank. Let's talk numbers for a sec. Trading at a forward P/E of 16.67, Amgen's looking like a bargain compared to its industry peers. It's like finding a designer suit at a thrift store price! And with analysts projecting solid growth, I think there's room for the stock to run. Sure, there are always risks in biotech, but Amgen's track record and pipeline make me think they've got more tricks up their sleeve. It's not all smooth sailing, but hey, what fun would investing be without a little choppy water? All in all, I'm feeling bullish on Amgen. It might not be a moonshot, but I see it as a solid rocket with plenty of fuel left. What do you think? Ready to hop on board?

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at William Blair.

Amgen Inc. (NASDAQ: AMGN) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $360.00 to $330.00. They now have an "outperform" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Piper Sandler from $344.00 to $310.00. They now have an "overweight" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) had its "overweight" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $310.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $324.00 price target on the stock.

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Co. from $256.00 to $275.00. They now have an "underperform" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Piper Sandler from $310.00 to $329.00. They now have an "overweight" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Co. from $275.00 to $294.00. They now have an "underperform" rating on the stock.

Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $324.00 to $320.00. They now have an "outperform" rating on the stock.